文献速递细菌感染、耐药与抗菌药物医院感染防控

头孢洛扎/他唑巴坦与多黏菌素或氨基糖苷类方案治疗耐药铜绿假单胞菌感染的比较

Ceftolozane/Tazobactam vs Polymyxin or Aminoglycoside-based Regimens for the Treatment of Drug-resistant Pseudomonas aeruginosa.
PubMed 文献 · Clin Infect Dis · 2020-01-01

该回顾性多中心观察性队列纳入200例耐药铜绿假单胞菌感染患者,比较头孢洛扎/他唑巴坦与多黏菌素或氨基糖苷类方案。校正混杂因素后,头孢洛扎/他唑巴坦与临床治愈独立相关且降低急性肾损伤风险,住院死亡率无差异。

要点

  • 头孢洛扎/他唑巴坦与更高临床治愈率独立相关(aOR 2.63)。
  • 头孢洛扎/他唑巴坦对急性肾损伤具保护作用(aOR 0.08)。
  • 两组住院死亡率无差异,结论支持优先选用头孢洛扎/他唑巴坦。

核心结论

  • 在耐药铜绿假单胞菌感染中,头孢洛扎/他唑巴坦较大幅度提高临床治愈并减少急性肾损伤,住院死亡率与多黏菌素或氨基糖苷类方案无差异。

研究设计与样本

  • 回顾性、多中心、观察性队列研究,共纳入200例患者,头孢洛扎/他唑巴坦组与多黏菌素或氨基糖苷类方案组各100例。
  • 采用多因素logistic回归,控制与治疗选择相关的因素,评估头孢洛扎/他唑巴坦对临床治愈、急性肾损伤和住院死亡率的独立影响。

主要发现

  • 队列病情较重:69%在重症监护室、63%接受机械通气、感染发生时42%为严重脓毒症或脓毒性休克。
  • 最常见感染类型为呼吸机相关性肺炎(52%),7%患者合并菌血症。
  • 多黏菌素/氨基糖苷组联合治疗使用率高于头孢洛扎/他唑巴坦组(72% vs 15%,P < .001)。
  • 校正组间差异后,头孢洛扎/他唑巴坦与临床治愈独立相关(aOR 2.63;95%CI 1.31-5.30),并对急性肾损伤具保护作用(aOR 0.08;95%CI 0.03-0.22)。
  • 住院死亡率无差异;头孢洛扎/他唑巴坦实现临床治愈的需治疗人数为5,多黏菌素/氨基糖苷类导致急性肾损伤的需伤害人数为4。

关键数值与推荐

  • 临床治愈:头孢洛扎/他唑巴坦校正后aOR 2.63(95%CI 1.31-5.30)。
  • 急性肾损伤:头孢洛扎/他唑巴坦校正后aOR 0.08(95%CI 0.03-0.22)。
  • 临床治愈需治疗人数为5;多黏菌素/氨基糖苷类致急性肾损伤需伤害人数为4。
  • 住院死亡率:两组无差异。

临床怎么用

  • 对耐药铜绿假单胞菌感染,可优先考虑头孢洛扎/他唑巴坦而非多黏菌素或氨基糖苷类方案,以争取更高临床治愈并减少急性肾损伤。
  • 本队列以呼吸机相关性肺炎为主且病情较重,结论外推至其他感染部位时需谨慎。

局限性

  • 为回顾性观察性队列研究,存在选择偏倚与残余混杂可能。
  • 两组联合治疗使用率差异明显(72% vs 15%),可能影响比较结果。
  • 样本量200例、单次研究,结论需前瞻性研究验证。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Ceftolozane/tazobactam is a novel cephalosporin/beta-lactamase inhibitor combination that often retains activity against resistant Pseudomonas aeruginosa. The comparative safety and efficacy vs polymyxins or aminoglycosides in this setting remains unknown. METHODS: A retrospective, multicenter, observational cohort study was performed. Patients who received ceftolozane/tazobactam were compared with those treated with either polymyxin or aminoglycoside-based regimens for infections due to drug-resistant P. aeruginosa. Multivariate logistic regression was performed controlling for factors associated with treatment to assess the independent impact of ceftolozane/tazobactam on clinical cure, acute kidney injury (AKI), and in-hospital mortality. RESULTS: A total of 200 patients were included (100 in each treatment arm). The cohort represented an ill population with 69% in the intensive care unit, 63% mechanically ventilated, and 42% in severe sepsis or septic shock at infection onset. The most common infection type was ventilator-associated pneumonia (52%); 7% of patients were bacteremic. Combination therapy was more commonly used in polymyxin/aminoglycoside patients than those who received ceftolozane/tazobactam (72% vs 15%, P < .001). After adjusting for differences between groups, receipt of ceftolozane/tazobactam was independently associated with clinical cure (adjusted odds ratio [aOR], 2.63; 95% confidence interval [CI], 1.31-5.30) and protective against AKI (aOR, 0.08; 95% CI, 0.03-0.22). There was no difference in in-hospital mortality. The number needed to treat for a clinical cure with ceftolozane/tazobactam was 5, and the number needed to harm with AKI with a polymyxin/aminoglycoside was 4. CONCLUSIONS: These data support the preferential use of ceftolozane/tazobactam over polymyxins or aminoglycosides for drug-resistant P. aeruginosa infections.

来源:Clin Infect Dis,查看原文。版权归原作者所有。

引用

  1. Pogue JM, Kaye KS, Veve MP, et al. Ceftolozane/Tazobactam vs Polymyxin or Aminoglycoside-based Regimens for the Treatment of Drug-resistant Pseudomonas aeruginosa. Clin Infect Dis. 2020. PMID: 31545346. doi:10.1093/cid/ciz816

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。